Regenerative potential of platelets in patients with chronic kidney disease

  • Elżbieta Cecerska-HeryćEmail author
  • Rafał Heryć
  • Magda Wiśniewska
  • Anna Michalczyk
  • Barbara Dołęgowska
Nephrology - Original Paper



Chronic kidney disease (CKD) is a systemic disease affecting many organs. Progression of renal failure aggravates ongoing inflammation and increases oxidative stress. In the final stage of CKD, it is necessary to use renal replacement therapy. A side effect of dialysis therapy is the synthesis of proinflammatory factors and increased oxidative stress, which activates platelets and immune cells.

Aim of the study

To determine the regenerative potential of platelets in patients with CKD based on the analysis of the relationships between substances with potential regenerative action, as well as analysis of the influence of the type of renal replacement therapy used on regeneration of platelets.

Materials and methods

The study group consisted of 117 patients. Based on the type of therapy used, patients were divided into four groups: hemodialysis, peritoneal dialysis, kidney transplant patients, and conservative treatment (30, 30, 27, and 30 patients). The control group consisted of 30 healthy volunteers. The concentrations of IGF-1, TGF-β, and PDGF-B in the blood serum were measured by ELISA methods.


It was shown that renal replacement therapy significantly influences the concentration of platelet growth factors (IGF-1: p = 0.025 and PDGF-B: p = 0.012). There was a relationship between the type of renal replacement therapy and the duration of dialysis, and the concentration of IGF-1, PDGF-B (p < 0.00001, p < 0.001).


The type of renal replacement therapy has a different effect on the concentration of platelet-derived growth factors IGF-1 and PDGF-B. PD patients had the highest concentrations of all growth factors, and this may be due to the presence of inflammation induced by dialysis-related advanced end-products of glycosylation (AGE).


Platelet growth factors IGF-1 PDGF-B TGF-β Chronic kidney disease 



This paper was funded by NCN 2011/01/B/NZ5/04235 and by Pomeranian Medical University no. MB-134-141/15.


  1. 1.
    Sánchez-González DL, Méndez-Bolaina E, Trejo-Bahena NI (2012) Platelet-rich plasma peptides: key for regeneration. Int J Pept 2012:532519CrossRefGoogle Scholar
  2. 2.
    Rendu F, Brohard-Bohn B (2001) The platelet release reaction: granules’ constituents, secretion and functions. Platelets 12:261–273CrossRefGoogle Scholar
  3. 3.
    Cole B, Seroyer S (2010) Platelet-rich plasma: where are we now and where are we going? Sports Health 2:203–210CrossRefGoogle Scholar
  4. 4.
    Liu Y, Kalen A, Risto O, Wahlström O (2002) Fibroblast proliferation due to exposure to a platelet concentrate in vitro is pH dependent. Wound Repair Regener 10:336–340CrossRefGoogle Scholar
  5. 5.
    Hosgood G (1993) Wound healing: the role of platelet-derived growth factor and transforming growth factor beta. Vet Surg 22:490–495CrossRefGoogle Scholar
  6. 6.
    Antoniades HN, Williams LT (1983) Human platelet-derived growth factor: structure and function. Feder Proc 42:2630–2634Google Scholar
  7. 7.
    Ece A, Gürkan F, Kervancioglu M, Kocamaz H, Gunes A et al (2006) Oxidative stress, inflammation and early cardiovascular damage in children with chronic renal failure. Pediatr Nephrol 21:545–552CrossRefGoogle Scholar
  8. 8.
    Floege J, Eitner F, Alpers CE (2008) A new look at platelet-derived growth factor in renal disease. J Am Soc Nephrol 19:12–23CrossRefGoogle Scholar
  9. 9.
    Wahlström O, Linder C, Kalén A, Magnusson P (2008) Acidic preparations of platelet concentrates release bone morphogenetic protein-2. Acta Orthop 79:433–437CrossRefGoogle Scholar
  10. 10.
    Betsholtz C (1995) Role of platelet-derived growth factors in mouse development. Int J Dev Biol 39:817–825Google Scholar
  11. 11.
    Bir SC, Esaki J, Marui A (2011) Therapeutic treatment with sustained-release platelet-rich plasma restores blood perfusion by augmenting ischemia-induced angiogenesis and arteriogenesis in diabetic mice. J Vasc Res 48:195–205CrossRefGoogle Scholar
  12. 12.
    Pierce GF, Mustoe TA, Lingelbach J, Masakowski VR, Gramates P et al (1989) Transforming growth factor β reverses the glucocorticoid-induced wound healing deficit in rats. Possible regulation in macrophages by platelet-derived growth factor. Proc Natl Acad Sci USA 86:2229–2233CrossRefGoogle Scholar
  13. 13.
    Böttinger EP, Bitzer M (2002) TGF-beta signaling in renal disease. J Am Soc Nephrol 13:2600–2610CrossRefGoogle Scholar
  14. 14.
    Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E (1990) Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature 346:371–374CrossRefGoogle Scholar
  15. 15.
    Border WA, Okuda S, Nakamura T, Languino LR, Ruoslahti E (1991) Role of TGF-beta 1 in experimental glomerulonephritis. Ciba Found Symp 157:178–189Google Scholar
  16. 16.
    Sharma K, Ziyadeh FN, Alzahabi B, McGowan TA, Kapoor S et al (1997) Increased renal production of transforming growth factor-b1 in patients with type II diabetes mellitus. Diabetes 46:854–859CrossRefGoogle Scholar
  17. 17.
    Ziyadeh FN (1994) Role of transforming growth factor beta in diabetic nephropathy. Exp Nephrol 2:137Google Scholar
  18. 18.
    Roberts AB (1998) Molecular and cell biology of TGF-beta. Miner Electrolyte Metab 24:111–119CrossRefGoogle Scholar
  19. 19.
    Filus A, Zdrojewicz Z (2014) Insulinopodobny czynnik wzrostu-1 (IGF-1)—budowai rola w organizmie człowieka. Pediatr Endocrinol Diabetes Metab 22(4):161–169CrossRefGoogle Scholar
  20. 20.
    Kratzsch J, Blum WF, Schenker E et al (1995) Regulation of growth hormone (GH), insulin-like growth factor IGF-1, IGF binding proteins 1,-2,-3 and GH binding protein during progression of liver cirrhosis. Exp Clin Endocrinol Diabetes 103:285–291CrossRefGoogle Scholar
  21. 21.
    Iglesias P, Diez JJ, Fernandez-Reyes MJ et al (2004) Growth hormone, IGF-1 and its binding proteins (IGFBP-1, and-3) in adult uraemic patients undergoing peritoneal dialysis and haemodialysis. Clin Endocrinol (Orf) 60:741–749CrossRefGoogle Scholar
  22. 22.
    Jia T, Gama Axelsson T, Heimbürger O, Bárány P, Lindholm B et al (2014) IGF-1 and survival in ESRD. Clin J Am Soc Nephrol 9:120–127CrossRefGoogle Scholar
  23. 23.
    Vasan RS, Sullivan LM, D’Agostino RB, Roubenoff R, Harris T et al (2003) Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study. Ann Intern Med 139:642–648CrossRefGoogle Scholar
  24. 24.
    Bach LA, Hale LJ (2015) Insulin-like growth factors and kidney disease. Am J Kidney Dis 65:327–336CrossRefGoogle Scholar
  25. 25.
    Nicolini D, Mocchegiani F, Palmonella G, Coletta M, Brugia M et al (2015) Postoperative insulin-like growth factor 1 levels reflect the graft’s function and predict survival after liver transplantation. PLoS One 17:10Google Scholar
  26. 26.
    Salso A, Tisone G, Tariciotti L, Lenci I, Manzia TM et al (2014) Relationship between GH/IGF-1 axis, graft recovery, and early survival in patients undergoing liver transplantation. BioMed Res Int 2014:6CrossRefGoogle Scholar
  27. 27.
    Reinhard M, Frystyk J, Jespersen B, Randers E, Bjerre M et al (2014) Impaired postprandial response of the insulin-like growth factor system in maintenance haemodialysis. Clin Endocrinol (Oxf) 80:757–765CrossRefGoogle Scholar
  28. 28.
    Youngman O (2012) The insulin-like growth factor system in chronic kidney disease: pathophysiology and therapeutic opportunities. Kidney Res Clin Pract 31:26–37CrossRefGoogle Scholar
  29. 29.
    Franklin SC, Moulton M, Sicard GA, Hammerman MR, Miller B (1997) Insulin-like growth factor I preserves renal function postoperatively. Am J Physiol 272:F257–F259Google Scholar
  30. 30.
    Vijayan A, Franklin SC, Behrend T, Hammerman MR, Miller B (1999) Insulin-like growth factor I improves renal function in patients with end-stage chronic renal failure. Am J Physiol 276:R929–R934Google Scholar
  31. 31.
    Hammerman MR, Miller SB (1997) Effects of growth hormone and insulin-like growth factor I on renal growth and function. J Pediatr 131:S17–S19CrossRefGoogle Scholar
  32. 32.
    Lowman HB, Chen YM, Skelton NJ, Mortensen DL, Tomlinson EE et al (1998) Molecular mimics of insulin-like growth factor 1 (IGF-1) for inhibiting IGF-I: IGF-binding protein interactions. Biochemistry 37:8870–8878CrossRefGoogle Scholar
  33. 33.
    Nilsson E, Carrero JJ, Heimbürger O, Hellberg O, Lindholm B et al (2016) A cohort study of insulin-like growth factor 1 and mortality in haemodialysis patients. Clin Kidney J 9:148–152CrossRefGoogle Scholar
  34. 34.
    Kocyigit I, Yilmaz MI, Simşek Y, Unal A, Sipahioglu MH et al (2013) The role of platelet activation in determining response to therapy in patients with primary nephrotic syndrome. Platelets 24:474–479CrossRefGoogle Scholar
  35. 35.
    Li X, Wu TT, Chen J, Qiu W (2017) Elevated expression levels of serum insulin-like growth factor-1, tumor necrosis factor-α and vascular endothelial growth factor 165 might exacerbate type 2 diabetic nephropathy. J Diabetes Investig 8:108–114CrossRefGoogle Scholar
  36. 36.
    Liu C, Zhang Y, Yuan L, Fu L, Mei C (2013) Rosiglitazone inhibits insulin-like growth factor-1-induced polycystic kidney disease cell growth and p70S6 kinase activation. Mol Med Rep 8:861–864CrossRefGoogle Scholar
  37. 37.
    Tarantini S, Valcarcel-Ares NM, Yabluchanskiy A, Springo Z, Fulop GA et al (2017) Insulin-like growth factor 1 deficiency exacerbates hypertension-induced cerebral microhemorrhages in mice, mimicking the aging phenotype. Aging Cell 16:469–479CrossRefGoogle Scholar
  38. 38.
    Miyajima A, Chen J, Lawrence C, Ledbetter S, Soslow RA et al (2000) Antibody to transforming growth factor-beta ameliorates tubular apoptosis in unilateral ureteral obstruction. Kidney Int 58:2301–2313CrossRefGoogle Scholar
  39. 39.
    Ziyadeh FN, Hoffman BB, Han DC, Iglesias-De La Cruz MC, Hong SW et al (2000) Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal anti-transforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 97:8015–8020CrossRefGoogle Scholar
  40. 40.
    Iwano M, Kubo A, Nishino T, Sato H, Nishioka H et al (1996) Quantification of glomerular TGF-beta 1 mRNA in patients with diabetes mellitus. Kidney Int 49:1120–1126CrossRefGoogle Scholar
  41. 41.
    Yamamoto T, Nakamura T, Noble NA, Ruoslahti E, Border WA (1993) Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 90(1814–1818):12Google Scholar
  42. 42.
    Bodi I, Kimmel PL, Abraham AA, Svetkey LP, Klotman PE et al (1997) Renal TGF-beta in HIV-associated kidney diseases. Kidney Int 51:1568–1577CrossRefGoogle Scholar
  43. 43.
    Mekki K, Taleb W, Biuzidi N, Kaddous A, Bouchenak M (2010) Effect of hemodialysis and peritoneal dialysis on redox status in chronić renal failure patients: a comparative study. Lipids Health Dis 2010:9–93Google Scholar
  44. 44.
    Mehta T, Buzkova P, Kizer JR, Djousse L et al (2017) Higher plasma transforming growth factor (TGF)-β is associated with kidney disease in older community dwelling adults. BMC Nephrol 21(18):98CrossRefGoogle Scholar
  45. 45.
    Chimenz R, Lacquaniti A, Colavita L, Chirico V, Fede C et al (2016) High mobility group box 1 and tumor growth factor β: useful biomarkers in pediatric patients receiving peritoneal dialysis. Ren Fail 38:1370–1376CrossRefGoogle Scholar
  46. 46.
    Zhou Q, Bajo MA, Del Peso G, Yu X, Selgas R (2016) Preventing peritoneal membrane fibrosis in peritoneal dialysis patients. Kidney Int 90:515–524CrossRefGoogle Scholar
  47. 47.
    Cina D, Patel P, Bethune JC, Thoma J, Rodriguez-Lecompte JC et al (2009) Peritoneal morphological and functional changes associated with platelet-derived growth factor B. Nephrol Dial Transplant 24:448–457CrossRefGoogle Scholar
  48. 48.
    Yamada K, Hatakeyama E, Sakamaki T, Nishimura M, Arita S et al (2001) Involvement of platelet-derived growth factor and histocompatibility of DRB 1 in chronic renal allograft nephropathy. Transplantation 15(71):936–941CrossRefGoogle Scholar
  49. 49.
    Monroy MA, Fang J, Li S, Ferrer L, Birkenbach MP et al (2015) Chronic kidney disease alters vascular smooth muscle cell phenotype. Front Biosci (Landmark Ed) 20:784–795CrossRefGoogle Scholar

Copyright information

© Springer Nature B.V. 2019

Authors and Affiliations

  1. 1.Department of Laboratory MedicinePomeranian Medical University of SzczecinSzczecinPoland
  2. 2.Department of Nephrology, Transplantology and Internal MedicinePomeranian Medical University of SzczecinSzczecinPoland
  3. 3.Department of PsychiatryPomeranian Medical University of SzczecinSzczecinPoland

Personalised recommendations